Coherus BioSciences (CHRS) Misses Q1 EPS by 205c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $0.88 +8.64%
EPS Growth %: +39.4%
Financial Fact:
Net sales: 481.26M
Today's EPS Names:
ATS, SICP, FTCO, More
EPS Growth %: +39.4%
Financial Fact:
Net sales: 481.26M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q1 EPS of ($0.35), $2.05 worse than the analyst estimate of $1.70. Revenue for the quarter came in at $7.6 million versus the consensus estimate of $54.36 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- William Blair Downgrades Fidelity National Information Services (FIS) to Market Perform
- United Therapeutics Corp. (UTHR) PT Raised to $768 at BTIG
- Intel (INTC) Jumps on Lip Bu Tan Insider Purchase
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
